Biotech earnings into full swing Thursday

Genentech started the biotech earnings season on a mixed note last Thursday as second quarter earnings beat the Street's estimates, but its outlook was less than stellar. Biotech might take a backseat to tech bellwethers Microsoft and Google Thursday, but big biotech Gilead reports Thursday and other big biotechs Amylin, Biogen, Genzyme, Celgene and Amgen report next week.

Here is what the Street is expecting from biotech's second quarter.

Gilead (GILD): EPS: $0.39 (39% growth), Revenues: $1.02B (49% growth)
Amylin (AMLN): EPS: $-0.34 (10%), Revenues: $198M (67%)
Biogen (BIIB): EPS: $0.63 (11%), Revenues: $759M (15%)
Genzyme (GENZ): EPS: $0.81 (19%), Revenues: $912M (15%)
Celgene (CELG): EPS: $0.23 (109%), Revenues: $318M (61%)
Amgen (AMGN): EPS: $1.06 (1%), Revenues: $3.69B (2%)